Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Participants needed: 1,800
Trial details
Phase: Phase 3Age: 18-85Biological sex: AllType: InterventionalSponsor: CytokineticsUpdated: Jun 24, 2026Locations: 188
Eligibility criteria

Are between ≥ 18 years and ≤ 85 years at the signing of informed consent [+12]

Have AFF on the screening ECG and are currently taking digoxin [+12]

Read more
Status: Recruiting

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

Participants needed: 60
Trial details
Phase: Phase 2Age: 40-85Biological sex: AllType: InterventionalSponsor: CytokineticsUpdated: May 29, 2026Locations: 25
Eligibility criteria

Males and females ≥ 40 years and ≤ 85 years of age at screening. [+6]

History or evidence of any other clinically significant disorder, malignancy, ac... [+1]

Read more
Status: Recruiting

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Participants needed: 55
Trial details
Phase: Phase 2, Phase 3Age: 12-17Biological sex: AllType: InterventionalSponsor: CytokineticsUpdated: Apr 13, 2026Locations: 38
Eligibility criteria

Period 1: Treatment Period [+14]

Period 1: Treatment Period [+15]

Read more